Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies Workshop

Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies Workshop

January 28, 2020
January 29, 2020

Location: 

January 28th 8:30am - 5:00pm
January 29th 8:45am - 4:15pm
Natcher Auditorium, Building 45, NIH Main Campus

Event Description: 

Register for Workshop on Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) are co-hosting a Workshop on Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies.

Current adeno-associated virus (AAV) manufacturing capacity cannot keep pace with the demand for AAV gene therapy clinical trials. The purpose of the meeting is to bring together thought leaders, key stakeholders and innovators to explore obstacles and identify opportunities for expanding the capacity of AAV manufacturing for rare disease gene therapies.

Workshop sessions will explore:

  • Prominent manufacturing formats and technologies
  • Major logistical bottlenecks
  • Strategies to streamline scale transitions
  • Master file best practices and opportunities
  • Analytics and lot release testing
  • Prospects for innovation, and barriers to innovation

You can learn more about the event and register at https://events-support.com/events/NCATS_Gene_Therapies_January_2020

If you are unable to attend the seminar in person, you may watch the videocast live or later at https://videocast.nih.gov.

REASONABLE ACCOMMODATIONS: Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact Deanna Portero or call (301) 451-9968, and/or the Federal Relay Service (1-800-877-8339). Requests should be made at least two business days in advance of the event.